Microglia Progenitor Cell Isolation for Faster CNS Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for deriving human microglia cells are time-consuming, associated with tumor risks, have low efficiency, and raise ethical concerns, limiting their use in treating CNS pathologies like glioblastoma and neurodegenerative disorders.
Innovation Solution
Isolation and expansion of CD11b+, CD45− microglia progenitor cells from bone marrow, placenta, or umbilical cord stromal cells, using mesenchymal stem cells (MSCs) in a serum-free medium with growth factors to rapidly generate an enriched population of microglia cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If induced pluripotent cells are used to derive microglia, then microglia cells can be obtained, but the process is time-consuming (>1/2 year), associated with tumor risks, and has low efficiency
Solution Approach 1:
The patent extracts and utilizes microglia progenitor cells directly from bone marrow stromal cells, bypassing the complex induced pluripotent cell reprogramming process. This direct extraction approach eliminates the time-consuming differentiation stages and tumor risks associated with iPSC methods while maintaining microglia derivation capability
Solution Approach 2:
The patent performs preliminary isolation and expansion of microglia progenitor cells from bone marrow stromal cells before differentiation. By preparing the progenitor cell population in advance with specific surface markers (CD11b+, CD45−), the subsequent differentiation to mature microglia is accelerated and more efficient
2Reliability
If induced pluripotent cells are used to derive microglia, then microglia cells can be obtained, but the efficiency is low
Solution Approach 1:
The patent introduces microglia progenitor cells as an intermediary population between bone marrow stromal cells and mature microglia. This intermediary stage with defined surface markers (CD11b+, CD45−) serves as a bridge that enhances derivation efficiency by selecting committed precursors that are primed for microglia differentiation, avoiding the low efficiency of direct iPSC conversion
3Reliability
If embryonic stem cells are used, then microglia cells can be derived, but ethical concerns arise and access is limited
Solution Approach 1:
The patent utilizes bone marrow stromal cells, which are readily accessible from patient samples or cell banks, replacing the need for ethically controversial embryonic stem cells. These stromal cells can be easily obtained and expanded, providing an ethical alternative that improves accessibility and ease of manufacture while maintaining the ability to derive microglia
4Reliability
If differentiation procedures are used to generate microglia-like cells, then microglia populations can be obtained, but the process is time-consuming
Solution Approach 1:
The patent employs parameter changes in the form of specific growth factors and culture conditions to accelerate the differentiation of microglia progenitor cells. By optimizing culture parameters (growth factors, serum-free media, co-culture with MSCs), the differentiation process is significantly shortened while maintaining high quality microglia population with proper surface marker expression (CD11b+, CD45−)
Data Source
AI summary
The present disclosure concerns a microglia progenitor cell derived from bone marrow and/or placental stromal cells and/or umbilical cord stromal cell and methods for their isolation; as well as use of said cells for therapy of disorders of the CNS.